Sign In
Free Newsletter
NJ hospitals invest in advanced prostate cancer care
New Jersey hospitals are expanding prostate cancer treatment with robotics, proton therapy and precision medicine innovations.
Why many men skip preventive care, miss cancer screenings
Doctors warn men who skip preventive care and cancer screenings face higher risks of late-stage diagnoses and costly treatment.
Bayer sues J&J over prostate cancer drug ads
Bayer filed suit against Johnson & Johnson, alleging false advertising of prostate cancer drug Erleada harmed sales of its rival treatment Nubeqa.
J&J completes $3.05B Halda Therapeutics acquisition
The addition of the Connecticut biotech expands Johnson & Johnson's oncology pipeline in prostate cancer and solid tumor treatments.
J&J to acquire Connecticut biotech in $3.05B oncology deal
Johnson & Johnson's latest target, Halda Therapeutics, will add prostate cancer therapy HLD-0915 along with other early-stage assets.
J&J to acquire cancer drug developer Ambrx for $2B
According to the New Brunswick-based buyer, the addition of the clinical-stage biopharmaceutical company presents a distinct opportunity to design, develop and commercialize targeted oncology therapeutics.
Quest Diagnostics unveils consumer, clinical tests
The first is an at-home kit that helps people understand their potential risk of developing certain inheritable health conditions, while the other aims to identify and differentiate potentially aggressive cases of prostate cancer.
University Hospital offers advanced prostate cancer treatment
"With this single-port robotic surgery technique, we are working to get patients home the same day, allowing patients to recover at home and reduce the stress on the healthcare system," said Dr. Evan Kovac.
Atlantic Health adds robotic tech to treatment options
Physicians at the provider's Rockaway location can now use Focal One to treat prostate cancer.
Mountainside Medical OK’d to use ‘life-changing’ cancer therapy
The Montclair facility said it is the first in New Jersey to offer Pluvicto, a treatment for the prostate that "limits damage to other cells and improve[s] outcomes for patients."
